GS-005 Outcomes by liver function in patients with unresectable hepatocellular carcinoma treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DWtrial

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2025-05-01 DOI:10.1016/S0168-8278(25)00302-2

Bruno Sangro, Masatoshi Kudo, Thomas Decaens, Matthias Pinter, Thomas Yau, Shukui Qin, Leonardo da Fonseca, Hatim Karachiwala, Joong-Won Park, Edward J. Gane, David Tai, Armando Santoro, Gonzalo Pizarro, Chang-Fang Chiu, Michael Schenker, Aiwu Ruth He, Nan Hu, Joseph Hreiki, Maria-Jesus Jimenez Exposito, Peter R. Galle

引用次数: 0

查看原文本刊更多论文

GS-005在CheckMate 9dw试验中，nivolumab联合ipilimumab与lenvatinib或sorafenib治疗的不可切除肝细胞癌患者的肝功能结局

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.